SCHEMBL5259397

SCHEMBL5259397

Cc1cc(C)nc(Nc2cccc(-c3nc4ccccc4s3)c2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.60
RAB9A P51151 5/20 0.60
NPC1 O15118 3/20 0.60
KDM4E B2RXH2 2/20 0.60
GAA P10253 2/20 0.60
EGFR P00533 3/20 0.59
IGF1R P08069 3/20 0.59
SRC P12931 3/20 0.59
KDR P35968 3/20 0.59
AURKB Q96GD4 2/20 0.59
AURKA O14965 2/20 0.59
INSR P06213 2/20 0.59
FLT4 P35916 2/20 0.59
MAPT P10636 9/20 0.54
TEK Q02763 2/20 0.54
NFKB1 P19838 3/20 0.53
NFKB2 Q00653 3/20 0.53
RELA Q04206 3/20 0.53
LMNA P02545 3/20 0.53
MEN1 O00255 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5263632 0.87 APP (0.63) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL24586958 0.84 RAB9A (0.65) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5260053 0.81 TP53 (0.63) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5258486 0.81 SMN1; SMN2 (0.58) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5259792 0.80 MAPT (0.58) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5260609 0.79 RAB9A (0.55) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5259019 0.79 MAPT (0.64) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5260406 0.79 RAB9A (0.61) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5258236 0.79 AURKA (0.78) SMN1; SMN2RAB9ANPC1KDM4EGAA
SCHEMBL5260103 0.77 EGFR (0.62) SMN1; SMN2RAB9ANPC1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 SMN1; SMN2 1665/4885RAB9A 3722/4885NPC1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.